Hallal David
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Seer to Present Proteomics Data at HUPO 2026; CFO Transition Announced. Seer Inc. will share early results from its PRECISE-SG100K proteomics study with Nanyang Technological University at the HUPO 2026 conference. The company also announced a transition in its Chief Financial Officer role. These developments provide updates on the firm's scientific progress and leadership structure.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Kalaris Therapeutics Moves in Pre-Market Amid Low RSI. Kalaris Therapeutics was highlighted in a roundup of health care stocks moving in Wednesday's pre-market session. The stock is currently trading near its 52-week low, with the RSI indicating oversold conditions. Analysts maintain a wide range of price targets for the company, reflecting varying views on its future performance.
Transaction History
| SRRK | ▼ Sell | Gift | 36,652 | $0 | 9/21/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 30,615 | $1.5M | 4/16/2026 | View on chart |
| SRRK | ▲ Buy | Grant | 128,004 | $0 | 2/9/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 57,450 | $2.5M | 1/13/2026 | View on chart |
| SRRK | ▼ Sell | Gift | 205,000 | $0 | 10/8/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 250,000 | $0 | 4/27/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 1,250,000 | $0 | 4/27/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 13,500 | $0 | 6/27/2024 | View on chart |
| SEER | ▲ Buy | Grant | 58,178 | $0 | 6/12/2024 | View on chart |
| KLRS | ▲ Buy | Grant | 35,000 | $0 | 6/6/2024 | View on chart |
| SEER | ▲ Buy | Grant | 23,443 | $0 | 6/14/2023 | View on chart |
| KLRS | ▲ Buy | Grant | 35,000 | $0 | 5/11/2023 | View on chart |
| KLRS | ▼ Sell | Open Market | 600,000 | $5.1M | 10/19/2022 | View on chart |
| KLRS | ▼ Sell | Open Market | 400,000 | $2.9M | 9/29/2022 | View on chart |
| KLRS | ▲ Buy | Grant | 3,253,796 | $15.0M | 7/28/2022 | View on chart |
| KLRS | ▼ Sell | Open Market | 4,227 | $23K | 7/21/2022 | View on chart |
| SEER | ▲ Buy | Grant | 9,945 | $0 | 6/15/2022 | View on chart |
| KLRS | ▼ Sell | Open Market | 65,725 | $241K | 6/3/2022 | View on chart |
| KLRS | ▼ Sell | Open Market | 4,227 | $25K | 4/21/2022 | View on chart |
| KLRS | ▼ Sell | Open Market | 25,244 | $186K | 3/11/2022 | View on chart |
| KLRS | ▼ Sell | Open Market | 40,481 | $306K | 3/10/2022 | View on chart |
| KLRS | ▼ Sell | Open Market | 17,100 | $137K | 1/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA
Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.